The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Modern Treatment Tied to Low Disease Activity in Pregnant RA Patients

Modern Treatment Tied to Low Disease Activity in Pregnant RA Patients

February 24, 2021 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Many pregnant women with rheumatoid arthritis (RA) may achieve low disease activity in the third trimester with a modern treatment regimen that includes anti-tumor necrosis factor (TNF) medications, a recent study suggests.

You Might Also Like
  • From the Expert: New Insights into Treating Pregnant Patients with Rheumatic Disease
  • Tocilizumab Monotherapy May Sustain Low Disease Activity in RA Patients
  • Treat to Target: Rheumatoid Arthritis in Pregnant Patients

Researchers examined data on 309 patients with RA who were pregnant or trying to conceive and who were treated with modern treat-to-target medication regimen that included anti-TNF medications as well as low-dose prednisone and disease-modifying anti-rheumatic drugs (DMARDs). They compared outcomes for this group of women to results from a historic reference cohort of women treated from 2002 to 2010.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the modern treatment study cohort, 75.4% of women were in remission or had low disease activity before pregnancy, and this rose to 90.4% during pregnancy. By contrast, 33.2% of women in the historic reference cohort were in remission or had low disease activity before pregnancy, and this rose to 47.3% during pregnancy.

“I think the take-home message should be that clinicians should apply a treat-to-target approach before and during pregnancy,” said lead study author Dr. Hieronymus T.W. Smeele of Erasmus University Medical Center in Rotterdam, The Netherlands.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This will lead to 80–90% of patients in low disease activity during pregnancy,” Dr. Smeele says by email. “Hopefully our future research will show that low disease activity has a beneficial effect on the offspring as well.”

In the historic cohort, women were treated by their own rheumatologist according to the standards of that time for pregnancy, mainly using sulfasalazine, prednisone or no medication, the study team notes in Annals of the Rheumatic Diseases.1

In the modern cohort, 87 patients (47.3%) used an anti-TNF agent at some point during pregnancy, and 56 women used these medications during the third trimester. A total of 188 children were born to women in the modern cohort.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

After delivery, none of the women who received modern treatment had a severe increase in rheumatoid arthritis disease activity postpartum. But 5.7% of those in the historical reference cohort had a severe increase in disease activity postpartum.

In addition, 12.2% of the women who received modern treatment had a moderate increase in disease activity postpartum, compared with 21% of the historical reference cohort.

One limitation of the study is that researchers were unable to show whether the treat-to-target therapy approach, newer targeted therapies, such as anti-TNF agents, combination therapy or all of these things combined, may have contributed to disease outcomes. In addition, because researchers only examined data on women who were able to conceive, it’s possible that selection bias influenced the results.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Anti-TNF, anti-TNF agent, pregnancy, pregnant women, Rheumatoid Arthritis (RA), Women

You Might Also Like:
  • From the Expert: New Insights into Treating Pregnant Patients with Rheumatic Disease
  • Tocilizumab Monotherapy May Sustain Low Disease Activity in RA Patients
  • Treat to Target: Rheumatoid Arthritis in Pregnant Patients
  • Study Says Low Disease-Activity State Can Reduce Lupus Organ Damage

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)